Patent ID: 8951561
Filing Date: 2015-02-10
Classification: A61K,A61N,A61P

Abstract:
1. A pharmaceutical composition for treating cancer, comprising: at least one activatable pharmaceutical agent capable of activation and of causing non-lytic cancer cell death upon activation, wherein the at least one activatable pharmaceutical agent is a psoralen or a coumarin; at least one plasmonics-active agent capable of enhancing or modifying energy, wherein the at least one plasmonics-active agent is at least one member selected from the group consisting of gold, silver, platinum, palladium, nickel, ruthenium, rhenium, copper, and cobalt; at least one energy modulation agent capable of activating the at least one activatable pharmaceutical agent when energized, wherein the at least one energy modulation agent is at least one member selected from the group consisting of CdS, CsCl, ZnS, Er a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is in a form of a plasmonics enhanced photospectral therapy (PEPST) probe comprising (a) the at least one plasmonics active agent as a plasmonics active metal nanoparticle, (b) the at least one activatable pharmaceutical agent, and (c) the at least one energy modulation agent, and has a configuration selected from the following: